thrombin

(redirected from Prothrombin g20210a mutation)
Also found in: Thesaurus, Medical, Encyclopedia.
Related to Prothrombin g20210a mutation: Prothrombin 20210a mutation

throm·bin

 (thrŏm′bĭn)
n.
A protease in blood that facilitates blood clotting by converting fibrinogen to fibrin.

thrombin

(ˈθrɒmbɪn)
n
(Biochemistry) biochem an enzyme that acts on fibrinogen in blood causing it to clot

throm•bin

(ˈθrɒm bɪn)

n.
an enzyme of the blood plasma that catalyzes the conversion of fibrinogen to fibrin, the last step of the blood-clotting process.
[1895–1900; thromb (us) + -in1]
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.thrombin - an enzyme that acts on fibrinogen in blood causing it to clot
coagulase - an enzyme that induces coagulation
Translations

throm·bin

n. trombina, enzima presente en la sangre extravasada que cataliza en la conversión de fibrinógeno en fibrina.
References in periodicals archive ?
Epidemiology of prothrombin G20210A mutation in the mediterranean region.
Matched case-control study on factor V Leidenand the prothrombin G20210A mutation in patients with ischemic stroketransient ischemic attack up to the age of 60 years.
In her medical history, there were two risk factors for an arterial thrombosis: drospirenone-containing oral contraceptive use and the prothrombin G20210A mutation.
The risk of recurrent venous thromboembolism among heterozygous carriers of factor V Leiden or prothrombin G20210A mutation.
sup][4],[5] However, there was another research showed that the prevalence of thrombophilia is not increased in women with severe OHSS, screening for V Leiden and prothrombin G20210A mutation in an IVF general population is not cost-effective.
Factor V Leiden and Prothrombin G20210A mutation, but not methylentetrahydrofolatereductase C677T, are associated with recurrent miscarriages.
Molecular studies for prothrombin G20210A mutation and screening for hyperhomocysteinemia were not performed due to lack of facilities.
Contrary to that, only one CVT was observed among our older patients, in this case associated with a prothrombin G20210A mutation.
Portal vein thrombosis associated with a myeloproliferative disorder, prothrombin G20210A mutation, antiphospholipid syndrome, with repermeation during anticoagulant therapy.
antithrombin activity, homocysteine levels, and the presence of antiphospholipid antibodies, activated protein C resistance (APCR), and prothrombin G20210A mutation were analyzed via standard methods, as described elsewhere (5).

Full browser ?